Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will discuss the scientific basis for treating Alzheimer’s disease as a multi-protein disorder and highlight Annovis’ approach of targeting multiple neurotoxic proteins simultaneously through its lead drug candidate, buntanetap, which is currently in a pivotal Phase 3 clinical trial.
The presentation underscores a paradigm shift in Alzheimer’s research, moving from single-target therapies toward addressing the disease’s multifactorial pathology. Buntanetap, a once-daily oral therapy, inhibits the translation of multiple neurotoxic proteins—including APP and amyloid beta, tau, alpha-synuclein, and TDP-43—through a specific RNA-targeting mechanism of action. By tackling several pathological proteins at once, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
This announcement is significant because Alzheimer’s disease affects millions worldwide, and current treatments offer only symptomatic relief. Annovis’ multi-protein approach could potentially modify the course of the disease. The presentation at Fierce Biotech Week, a major industry conference, provides a platform for the company to share its scientific rationale with key stakeholders, including investors, researchers, and potential partners.
For more information, the full press release is available at https://ibn.fm/kZ2Z4. Annovis Bio, headquartered in Malvern, Pennsylvania, is a Phase 3 clinical-stage biotechnology company focused on neurodegenerative diseases. More details about the company and its pipeline can be found at www.annovisbio.com.
Investors can access the latest news and updates relating to ANVS in the company’s newsroom at https://ibn.fm/ANVS. The presentation at Fierce Biotech Week 2026 is expected to provide deeper insights into the science behind buntanetap and its potential to address the underlying causes of neurodegeneration.
